DMD Digital Health Connections Group Inc Asset Resilience Ratio

Latest as of March 2024: 15.49%

DMD Digital Health Connections Group Inc asset resilience ratio. DMD Digital Health Connections Group Inc (APTOF) has an Asset Resilience Ratio of 15.49% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can DMD Digital Health Connections Group Inc fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$1.98 Million
Cash + Short-term Investments

Total Assets

$12.80 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of DMD Digital Health Connections Group Inc (2014–2023)

Asset resilience ratio of DMD Digital Health Connections Group Inc from 2014 to 2023. This chart shows how DMD Digital Health Connections Group Inc's Asset Resilience Ratio has changed over time. Read APTOF liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down DMD Digital Health Connections Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of DMD Digital Health Connections Group Inc.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.98 Million 15.49%
Total Liquid Assets $1.98 Million 15.49%

Asset Resilience Insights

  • Good Liquidity Position: DMD Digital Health Connections Group Inc maintains a healthy 15.49% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

DMD Digital Health Connections Group Inc Industry Peers by Asset Resilience Ratio

Compare DMD Digital Health Connections Group Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

DMD Digital Health Connections Group Inc Asset Resilience Ratio by Year (2014–2023)

DMD Digital Health Connections Group Inc asset resilience ratio by year from 2014 to 2023. The table below shows the annual Asset Resilience Ratio data for DMD Digital Health Connections Group Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.00% $0.00 $12.99 Million --
2022-12-31 19.58% $9.99 Million $51.03 Million -28.91pp
2021-12-31 48.49% $40.01 Million $82.53 Million +23.99pp
2017-12-31 24.49% $8.60 Million $35.11 Million +6.96pp
2016-12-31 17.53% $5.76 Million $32.87 Million +12.17pp
2015-12-31 5.36% $1.42 Million $26.56 Million +5.20pp
2014-12-31 0.16% $28.00K $17.92 Million --
pp = percentage points

About DMD Digital Health Connections Group Inc

NASDAQ:APTOF USA Biotechnology
Market Cap
$4.31 Million
Market Cap Rank
#28795 Global
#5918 in USA
Share Price
$1.69
Change (1 day)
+0.00%
52-Week Range
$1.35 - $1.75
All Time High
$2.31
About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more